Ranitidine is a histamine type 2 (H2) receptor blocker drug available by prescription as well as over-the-counter (OTC). Ranitidine is used in treatment of intestinal & stomach ulcers, gastroesophageal reflux disease (GERD), and erosive esophagitis, and Zollinger-Ellison syndrome. Stomach ulcer or peptide ulcer causes open sores in the inner lining of stomach and upper portion of small intestine. Ranitidine helps to reduce excessive acid production in patient’s stomach. Increasing prevalence of risk factors to cause peptide ulcers in patients such as use of pain relievers, use of certain medications (steroids, low-dose aspirin, combination of selective serotonin reuptake inhibitors (SSRIs) with pain relievers), smoking, excessive alcohol consumption, untreated stress and easting of spicy foods; greatly increases the chance of developing ulcers.

Market Dynamics

Ranitidine market is expected to witness growth during the forecast period, owing to growing prevalence of gastroesophageal reflux disease (GERD) and stomach and intestinal ulcers, worldwide. For instance, a review study published in the Gut Journal in June 2014, estimated the range of GERD prevalence in global population, in 2014. This study reported GERD prevalence as 18%- 28% in North America, 9%-26% in Europe, 3%-8% in East Asia, 9%-33% in Middle East, 12% in Australia, and 23% in Latin America. According to this statistics, North America and Middle East are at higher risk to develop GERD disease.

Furthermore, higher efficacy and tolerability of ranitidine in suppression of stomach & intestinal ulcers is increasing the adoption of ranitidine-based medication in the market.   

Key features of the study

• This report provides in-depth analysis of ranitidine market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2026 - 2033), considering 2025, as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches and approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global ranitidine market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies and future plans
• Key companies covered as a part of this study include GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Strides Pharma Science Limited (Strides Shasun), Tocris Bioscience (R&D Systems), Merck KGaA, and Sun Pharmaceutical Industries Limited among others.
• Insights from this report would allow marketers and management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global ranitidine market report caters to various stakeholders in this industry including investors, suppliers, ranitidine-based product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the ranitidine market.

Market Segmentation

• By Strength (Revenue, USD Mn, 2021-2033)
  • 75 mg
  • 150 mg
  • 300 mg
• By Form (Revenue, USD Mn, 2021-2033)
  • Tablets
  • Syrup
  • Injection
• By Route of Administration (Revenue, USD Mn, 2021-2033)
  • Oral
  • Intravenous
• By Application (Revenue, USD Mn, 2021-2033)
  • Intestinal & Stomach Ulcers
  • Gastroesophageal Reflux Disease (GERD)
  • Esophagitis
  • Zollinger-Ellison Syndrome
  • Others
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Ranitidine Market, By Region: (Revenue, USD Mn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa 
• Key Players
  • GlaxoSmithKline plc
  • Boehringer Ingelheim GmbH
  • Strides Pharma Science Limited (StridesShasun)
  • Tocris Bioscience (R & D Systems)
  • Merck KGaA
  • Sun Pharmaceutical Industries Limited